Roche’s Cardiometabolic Head Has Lilly and Novo In His Crosshairs

Manu Chakravarthy, Roche’s head of the resurrected cardiometabolic division, lays out his four-pillared strategy to place the company in direct competition with Eli Lilly and Novo Nordisk.